Parul Patel1, Eleanor Howgate1, Paul Martin2, David J Carlile3, Leon Aarons1, Diansong Zhou4. 1. Manchester Pharmacy School, Manchester, UK. 2. AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK. 3. AstraZeneca, Early Clinical Development, Innovative Medicines and Early Development Biotech Unit, Da Vinci Building, Royston, Hertfordshire, UK. 4. AstraZeneca, Waltham, MA, USA.
Abstract
AIMS: The aims of the study were to characterize the pharmacokinetics (PK) of selumetinib (AZD6244; ARRY-142886), a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor in clinical development for various indications, and its N-desmethyl metabolite in healthy volunteers, and evaluate clinically important covariates. METHODS: A pooled-population PK analysis was performed using a nonlinear mixed-effects approach with plasma concentration data from 346 subjects who received single oral doses of selumetinib 20-75 mg across 10 phase I studies. Absolute bioavailability was determined using intravenous [14 C] selumetinib. RESULTS: A two-compartment linear model with sequential zero-first order absorption and a lag time for the zero-order process was described for selumetinib PK. N-desmethyl metabolite disposition was described by a single compartment with linear elimination, without back transformation. The parent-only and joint models generally described pooled data adequately. For the median subject, not taking interacting drugs, estimates for clearance (CL) and central volume of distribution (V2) for selumetinib in the final joint model were 12.7 l h-1 and 35.6 l, respectively. Food effects, comedication with itraconazole [a cytochrome P450 (CYP) 3A4 inhibitor], fluconazole (a CYP2C19 inhibitor) and rifampicin (a CYP3A4 inducer) and formulation effects were incorporated into the base model a priori. Race and hepatic function were also influential in the PK model. Additional covariates affecting selumetinib disposition identified from covariate analysis were age on V2, bilirubin on CL, and weight on CL and V2. CONCLUSIONS: Analysis confirmed previous clinical pharmacology study findings of drug-drug interactions and food effects, with additional covariates that influence selumetinib and N-desmethyl selumetinib PK identified. Dose modifications based on these additional covariates were not considered necessary.
AIMS: The aims of the study were to characterize the pharmacokinetics (PK) of selumetinib (AZD6244; ARRY-142886), a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor in clinical development for various indications, and its N-desmethyl metabolite in healthy volunteers, and evaluate clinically important covariates. METHODS: A pooled-population PK analysis was performed using a nonlinear mixed-effects approach with plasma concentration data from 346 subjects who received single oral doses of selumetinib 20-75 mg across 10 phase I studies. Absolute bioavailability was determined using intravenous [14 C] selumetinib. RESULTS: A two-compartment linear model with sequential zero-first order absorption and a lag time for the zero-order process was described for selumetinib PK. N-desmethyl metabolite disposition was described by a single compartment with linear elimination, without back transformation. The parent-only and joint models generally described pooled data adequately. For the median subject, not taking interacting drugs, estimates for clearance (CL) and central volume of distribution (V2) for selumetinib in the final joint model were 12.7 l h-1 and 35.6 l, respectively. Food effects, comedication with itraconazole [a cytochrome P450 (CYP) 3A4 inhibitor], fluconazole (a CYP2C19 inhibitor) and rifampicin (a CYP3A4 inducer) and formulation effects were incorporated into the base model a priori. Race and hepatic function were also influential in the PK model. Additional covariates affecting selumetinib disposition identified from covariate analysis were age on V2, bilirubin on CL, and weight on CL and V2. CONCLUSIONS: Analysis confirmed previous clinical pharmacology study findings of drug-drug interactions and food effects, with additional covariates that influence selumetinib and N-desmethyl selumetinib PK identified. Dose modifications based on these additional covariates were not considered necessary.
Authors: C Bazzoli; H Bénech; E Rey; S Retout; D Salmon; X Duval; J M Tréluyer; F Mentré Journal: Antimicrob Agents Chemother Date: 2011-05-16 Impact factor: 5.191
Authors: Tammie C Yeh; Vivienne Marsh; Bryan A Bernat; Josh Ballard; Heidi Colwell; Ron J Evans; Janet Parry; Darin Smith; Barbara J Brandhuber; Stefan Gross; Allison Marlow; Brian Hurley; Joe Lyssikatos; Patrice A Lee; James D Winkler; Kevin Koch; Eli Wallace Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531
Authors: Chandra Bartholomeusz; Xuemei Xie; Mary Kathryn Pitner; Kimie Kondo; Ali Dadbin; Jangsoon Lee; Hitomi Saso; Paul D Smith; Kevin N Dalby; Naoto T Ueno Journal: Mol Cancer Ther Date: 2015-09-17 Impact factor: 6.261
Authors: Angela W Dymond; Colin Howes; Christine Pattison; Karen So; Gabriella Mariani; Mark Savage; Stuart Mair; Gill Ford; Paul Martin Journal: Clin Ther Date: 2016-10-15 Impact factor: 3.393
Authors: Alex A Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt Journal: J Clin Oncol Date: 2008-04-07 Impact factor: 44.544
Authors: Suzanne Leijen; Patricia M M B Soetekouw; T R Jeffry Evans; Marianne Nicolson; Jan H M Schellens; Maria Learoyd; Lynda Grinsted; Victoria Zazulina; Thinn Pwint; Mark Middleton Journal: Cancer Chemother Pharmacol Date: 2011-09-28 Impact factor: 3.333
Authors: Y T Patel; V M Daryani; P Patel; D Zhou; J Fangusaro; D J Carlile; P D Martin; L Aarons; C F Stewart Journal: CPT Pharmacometrics Syst Pharmacol Date: 2017-03-22
Authors: Joyson J Karakunnel; Nam Bui; Latha Palaniappan; Keith T Schmidt; Kenneth W Mahaffey; Briggs Morrison; William D Figg; Shivaani Kummar Journal: J Transl Med Date: 2018-12-04 Impact factor: 5.531
Authors: Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel Journal: Curr Oncol Rep Date: 2021-03-15 Impact factor: 5.075